Breath biopsy to be used in COPD trial
As reported in The Pharma Times, GlaxoSmithKline is incorporating Owlstone Medical's, Breath Biopsy platform into the clinical development programme for its novel, experimental respiratory drug danirixin.
GSK will utilise Owlstone’s Breath Biopsy platform as part of a Phase II study that aims to assess whether it is possible to identify the right patient for the right treatment, as well as the treatment effects of a novel drug for chronic obstructive pulmonary disease (COPD).
The platform will be used to capture Volatile Organic Compounds (VOCs) in breath – which are produced by the body’s metabolism and relate directly to disease activity - completely non-invasively for “high sensitivity” analysis, Owlstone said.
The group’s Breath Biopsy clinical laboratory allows clinical and pharmaceutical partners to access comprehensive VOC biomarker discovery services and identify breath biomarkers for a range of precision medicine applications.